evidence: Ginger (Zingiber officinale), as an edible plant, is also considered as a traditional herbal medicine in China. Scientific evidence has demonstrated that ginger has broad anti-inflammatory properties through modulating cytokine production and other regulatory pathways [6,7,8,9]. Specifically, ginger exhibited a protective role against acute respiratory distress syndrome [10, 11], the primary cause of mortality in severe COVID-19 cases. Moreover, bioactive compounds present in ginger, such as gingerol and shogaol, showed high affinity to the SARS-CoV-2 spike protein, thus could potentially interfere with the spike protein and host angiotensin-converting enzyme 2 (ACE-2) interaction [12, 13]. Interactions between ginger-derived compounds and papain-like protease and other virus proteins essential for its survival were also indicated via computational theoretical models [14, 15]. Taken together, ginger presents the potential as an alternative therapeutic agent to treat COVID-19. Therefore, we conducted a clinical trial to examine the effect of the ginger supplement on the clinical manifestations of individuals with COVID-19. [...] In conclusion, this preliminary study suggested that supplementing individuals with COVID-19 with ginger could be a cost-effective strategy in the future treatment of COVID-19, and emphasized the importance of implementing ginger supplementation to the target population to achieve the best outcomes.